Osteoporosis Drugs: Rising Geriatric Population in APAC to drive Global Market at 4% CAGR by 2022

New York City, New York, August 25, 2015: Characterized by the thinning or weakening of bones and a high tendency of fractures, osteoporosis is a progressive skeletal disease. Persistence Market Research studies the osteoporosis drugs market in detail in a recent report titled “Global Market Study on Osteoporosis Drugs: Asia Pacific to Witness Highest Growth by 2022”. The 71-page research publication is available for sale on the company website.

According to the report, the global osteoporosis drugs market is anticipated to develop at a modest CAGR of 4.0% during the forecast period. The market has been pegged at US$11,226.1 million in 2015 and is projected to grow to US$14,786.7 million by 2022.

Buy Full Report: http://www.persistencemarketresearch.com/market-research/osteoporosis-drugs-market.asp

The global osteoporosis drugs market is segmented in the report on the basis of type of drugs and geography. The osteoporosis drugs studied in the research study include selective estrogen receptors modulators (SERMs), RANK ligand inhibitors, parathyroid hormone therapy drugs, bisphosphonates, and calcitonin.

Geographically, the global osteoporosis drugs market is divided into North America, Europe, and Asia Pacific. While North America is the largest osteoporosis drugs market, Asia Pacific has emerged as the fastest developing regional segment.

The increasing prevalence of osteoporosis mainly owing to alarming rate of obesity, growing geriatric population, and rising incidence of lifestyle-associated diseases drives the North American osteoporosis drugs market. The U.S. Department of Health and Human Services reveals that around 250,000 hip fractures in the U.S. are associated with osteoporosis. The National Osteoporosis Foundation states that in 2013, an estimated 54 million people in the U.S. above the age of 50 were affected by low bone mass and osteoporosis.

The European osteoporosis drugs market, the second largest regional segment, is also propelled by changing lifestyle, rise in geriatric population, and growing awareness about osteoporosis. The International Osteoporosis Foundation reveals that in 2010, an estimated 27.5 million people in Europe were affected by the condition and by 2030 this is expected to rise to 33.9 million. The 2010 figure comprised an astounding 22 million women and 5.5 million men.

Request Sample Report: http://www.persistencemarketresearch.com/samples/2983

Asia Pacific, emerging as the most rapidly developing regional market for osteoporosis drugs, is driven by similar factors as other regional markets. The International Osteoporosis Foundation indicates that by 2050, women in Asia will make up for approximately 50% of the world’s osteoporosis hip fractures. A study conducted by the National Centre for Biotechnology Information on Epidemiology in Osteoporosis in Japan showed that an estimated 15 million people suffered from osteoporosis in Japan in 2011.

The key players profiled in the osteoporosis drugs market report are Novo Nordisk A/S, F. Hoffmann-La Roche Ltd., GlaxoSmithKline plc, Novartis AG, Pfizer, Inc., Merck & Co, Inc., Actavis plc, Eli Lilly and Company, Amgen, Inc., and Teva Pharmaceutical Industries Ltd. These companies are profiled on the basis of company overview, financial performance, key developments, and products and services.

About Us

Persistence Market Research (PMR) is a U.S.-based full-service market intelligence firm specializing in syndicated research, custom research, and consulting services. PMR boasts market research expertise across the Healthcare, Chemicals and Materials, Technology and Media, Energy and Mining, Food and Beverages, Semiconductor and Electronics, Consumer Goods, and Shipping and Transportation industries. The company draws from its multi-disciplinary capabilities and high-pedigree team of analysts to share data that precisely corresponds to clients’ business needs.

PMR stands committed to bringing more accuracy and speed to clients’ business decisions. From ready-to-purchase market research reports to customized research solutions, PMR’s engagement models are highly flexible without compromising on its deep-seated research values.

Contact

Persistence Market Research

305 Broadway
7th Floor
New York City, NY 10007
United States
USA-Canada Toll Free: 800-961-0353
Email: sales@persistencemarketresearch.com
Web: http://www.persistencemarketresearch.com